# LDFWART With Docetaxel in Patients With Platinum-Resistant Recurrent Ovarian Carcinoma

> **NCT02083536** · PHASE1 · WITHDRAWN · sponsor: **University of Miami**

## Conditions studied

- Ovarian Cancer
- Ovarian Carcinoma
- Recurrent Ovarian Cancer
- Recurrent Ovarian Carcinoma

## Interventions

- **RADIATION:** Low Dose Fractionated Whole Abdominal Radiation Therapy
- **DRUG:** Docetaxel

## Key facts

- **NCT ID:** NCT02083536
- **Lead sponsor:** University of Miami
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2014-05
- **Primary completion:** 2019-05
- **Final completion:** —
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Study voluntarily stopped by Principal Investigator due to lack of accrual.
- **Last updated:** 2016-08-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02083536

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02083536, "LDFWART With Docetaxel in Patients With Platinum-Resistant Recurrent Ovarian Carcinoma". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT02083536. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*